Enveric Biosciences (ENVB) EBIT Growth (1y) (2011 - 2026)
Enveric Biosciences (ENVB) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | -36.55% |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - | -20.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.34% |
| Dec 31, 2025 | 30.87% |
| Sep 30, 2025 | 10.04% |
| Jun 30, 2025 | -32.73% |
| Mar 31, 2025 | 11.70% |
| Dec 31, 2024 | -33.11% |
| Sep 30, 2024 | 39.59% |
| Jun 30, 2024 | 67.02% |
| Mar 31, 2024 | 49.03% |
| Dec 31, 2023 | 80.54% |
| Sep 30, 2023 | 39.04% |
| Jun 30, 2023 | -22.27% |
| Mar 31, 2023 | -1.35% |
| Dec 31, 2022 | 75.96% |
| Sep 30, 2022 | -60.85% |
| Jun 30, 2022 | -39.96% |
| Mar 31, 2022 | 29.11% |
| Dec 31, 2021 | -1,346.91% |
| Sep 30, 2021 | -617.97% |
| Jun 30, 2021 | -338.17% |